Polyethylene glycol loxenatide versus liraglutide in treatment of patients with type 2 diabetes mellitus and morbide obesity
Qin Jing
You Zheng-yi
Zhang Hui
Zhao Mu-dan
Abstract：Objective To compare polyethylene glycol loxenatide with liraglutide in treatment of patients suffering from type 2 diabetes mellitus and severe obesity for suggesting a potent treatment protocol for the clinical management of this condition.Methods A total of 136 patients with type 2 diabetes mellitus and severe obesity admitted to Nanjing Tongren Hospital Affiliated to Southeast University School of Medicine from January 2022 to October 2023 were enrolled in this study and divided into two groups using the random number table method.The 68 patients in group A were administered polyethylene glycol loxenatide,while the other 68 in group B received liraglutide.Then the obesity physical-related indexes,lipid indicators,blood glucose indicators and the incidence of adverse reactions were compared between the two groups.Results A reduction in body weight,waist-to-hip ratio,body mass index(BMI)and waist circumference was observed in all patients after treatment,and group B had lower body weight((80.31±7.62)kg vs(83.65±7.93)kg)and BMI((24.13±1.82)kg·m-2 vs(25.34±1.84)kg·m-2)as compared with group A(body weight t=2.504,P=0.014;BMI t=3.855,P<0.05).A decrease in triglyceride(TG),total cholesterol(TC)and low density lipoprotein(LDL-C),and an increase in high density lipoprotein cholesterol(HDL-C)were observed in all patients after treatment(P<0.05).A decrease in 2-hour postprandial blood glucose(2 h FBG),postprandial blood glucose(FBG),hemoglobin A1c(HbAlc),and homeostasis model assessment of insulin resistance(HOMA-IR),and an increase in fasting insulin(FINS)and HOMA β cell function(HOMA-β)were detected in all patients after treatment,and group A reported a smaller 2 h FBG((7.86±1.12)mmol·L-1 vs(8.72±1.34)mmol·L-1)and FBG((6.18±0.71)mmol·L-1 vs(7.02±0.62)mmol·L-1),and larger HOMA-β((74.62±3.78)%vs(62.79±3.56)%)as compared with group B(2 h FBG t=4.061,P<0.05;FBG t=7.349,P<0.05;HOMA-β t=18.937,P<0.05).The adverse reaction rate demonstrated no statistical difference between the two groups(20.59%vs 25.00%,χ2=0.376,P=0.540).Conclusion For patients with type 2 diabetes mellitus and morbide obesity,both polyethylene glycol loxenatide and liraglutide are effective in reducing body weight,controlling blood lipids,lowering blood glucose,as well as enhancing pancreatic β-cell function,and the safety profile is similar.However,liraglutide is more advantageous in reducing body weight,while polyethylene glycol loxenatide is more effective in improving pancreatic β-cell function and lowering blood glucose.
Keywords：ObesityType 2 diabetes mellitusPolyethylene glycol loxenatideLiraglutideFunction of islet beta cellBlood glucose
Publication Date：2024-06-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 226-229 )